Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Lu-PSMA for Oligometastatic Prostate Cancer Treated With STereotactic Ablative Radiotherapy, a Randomised Phase II Parallel Cohort Trial

NCT05560659 is registered in ClinicalTrials.gov with Peter MacCallum Cancer Centre, Australia as lead sponsor.

NCT NCT05560659
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05560659 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Lu-PSMA for Oligometastatic Prostate Cancer Treated With STereotactic Ablative Radiotherapy, a Randomised Phase II Parallel Cohort Trial
Lead sponsor
Peter MacCallum Cancer Centre, Australia
Phase
Phase 2
Overall status
Recruiting
Start date
December 14, 2023
Completion date
May 31, 2027
Enrollment
92 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

oligometastatic prostate cancer